Catalyst Pharmaceuticals appoints Mary Coleman to newly created IR role

Catalyst Pharmaceuticals has appointed Mary Coleman to the newly created position of vice president and head of investor relations. She reports to Patrick McEnany, CEO of Catalyst.

Coleman joins Catalyst with more than 20 years of investor relations and corporate communications experience in the biotechnology and specialty pharmaceutical industry.

Recently, she served as vice president of investor relations at BioXcel Therapeutics, a clinical stage biopharmaceutical company.

Previously, she was vice president of investor relations and communications at Jubilant Pharmaceuticals, a global integrated pharmaceutical company. She was also vice president of investor relations and corporate communications at BioDelivery Sciences International, a biotechnology company.

‘We are delighted to welcome Mary to the Catalyst team. Her extensive investor relations experience in the pharmaceutical industry and insights make her uniquely qualified to support our investor relations objectives,’ says McEnany in a press release.

‘In this newly created position, she will play an instrumental role in developing and implementing our investor relations program as we continue to execute our growth strategy and elevate our profile among the investment community.’